Total Payments
$340,374
2024 Payments
$2,161
Companies
54
Transactions
1,699
Medicare Patients
871
Medicare Billing
$102,617
Payment Breakdown by Category
Other$257,516 (75.7%)
Food & Beverage$37,426 (11.0%)
Travel$27,615 (8.1%)
Consulting$17,564 (5.2%)
Education$134.60 (0.0%)
Gifts$118.80 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $247,441 | 148 | 72.7% |
| Food and Beverage | $37,426 | 1,394 | 11.0% |
| Travel and Lodging | $27,615 | 128 | 8.1% |
| Consulting Fee | $17,564 | 12 | 5.2% |
| Honoraria | $10,075 | 4 | 3.0% |
| Education | $134.60 | 11 | 0.0% |
| Gift | $118.80 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $98,232 | 256 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $74,242 | 176 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $57,363 | 171 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $34,324 | 124 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $25,583 | 126 | $0 (2020) |
| Lilly USA, LLC | $16,972 | 177 | $0 (2024) |
| Orexigen Therapeutics, Inc. | $12,676 | 17 | $0 (2017) |
| ABBVIE INC. | $5,452 | 53 | $0 (2022) |
| Corcept Therapeutics | $3,930 | 62 | $0 (2024) |
| Amgen Inc. | $2,198 | 68 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,161 | 84 | Lilly USA, LLC ($718.83) |
| 2023 | $2,381 | 86 | Intuity Medical Inc ($543.48) |
| 2022 | $7,089 | 39 | Novo Nordisk Inc ($5,668) |
| 2021 | $20,135 | 166 | Novo Nordisk Inc ($12,262) |
| 2020 | $45,532 | 180 | Novo Nordisk Inc ($20,361) |
| 2019 | $66,574 | 281 | SANOFI-AVENTIS U.S. LLC ($16,942) |
| 2018 | $75,988 | 424 | Novo Nordisk Inc ($18,663) |
| 2017 | $120,514 | 439 | SANOFI-AVENTIS U.S. LLC ($35,164) |
All Payment Transactions
1,699 individual payment records from CMS Open Payments — Page 1 of 68
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Intra-Sana Laboratories | RELTONE 200 MG (Drug), GLYCATE, RELTONE 400 MG | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: GALLSTONES | ||||||
| 12/11/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $25.51 | General |
| Category: Cardio-renal | ||||||
| 12/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $28.28 | General |
| Category: DIABETES | ||||||
| 12/03/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $23.46 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 11/27/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: Durable Pump | ||||||
| 11/21/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $31.78 | General |
| Category: Obesity | ||||||
| 11/20/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $22.64 | General |
| Category: Diabetes | ||||||
| 11/13/2024 | Ascensia Diabetes Care Us Inc. | EVERSENSE 365 SENSOR KIT (RETAIL) (Device) | Food and Beverage | In-kind items and services | $21.50 | General |
| Category: Diabetes | ||||||
| 11/06/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $24.28 | General |
| Category: Diabetes | ||||||
| 11/05/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $22.23 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 10/29/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $30.43 | General |
| Category: HIV | ||||||
| 10/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $27.40 | General |
| Category: Cardio-renal | ||||||
| 10/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $31.28 | General |
| Category: DIABETES | ||||||
| 10/01/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 09/25/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $29.20 | General |
| Category: Diabetes | ||||||
| 09/19/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $10.03 | General |
| Category: Biological | ||||||
| 09/17/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $25.09 | General |
| Category: Diabetes | ||||||
| 09/11/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.04 | General |
| Category: Cardio-renal | ||||||
| 09/10/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $30.63 | General |
| Category: Endocrinology | ||||||
| 09/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.89 | General |
| Category: DIABETES | ||||||
| 09/03/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $24.64 | General |
| Category: Diabetes | ||||||
| 08/27/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $31.05 | General |
| Category: Diabetes | ||||||
| 08/22/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $19.65 | General |
| Category: Biological | ||||||
| 08/15/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: Diabetes | ||||||
| 08/13/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $23.65 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 12 | 27 | $8,585 | $4,205 |
| 2022 | 3 | 90 | 90 | $16,780 | $2,645 |
| 2021 | 5 | 400 | 647 | $125,010 | $51,863 |
| 2020 | 5 | 369 | 551 | $112,860 | $43,904 |
Total Patients
871
Total Services
1,315
Medicare Billing
$102,617
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 12 | 27 | $8,585 | $4,205 | 49.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 20 | 20 | $4,100 | $1,127 | 27.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 36 | 36 | $7,920 | $846.77 | 10.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 34 | 34 | $4,760 | $671.06 | 14.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 135 | 278 | $56,990 | $24,528 | 43.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 97 | 178 | $24,920 | $10,703 | 43.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 75 | 75 | $23,625 | $8,848 | 37.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 54 | 77 | $16,940 | $7,021 | 41.4% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Office | 2021 | 39 | 39 | $2,535 | $763.36 | 30.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 115 | 216 | $44,280 | $17,338 | 39.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 95 | 95 | $29,925 | $11,688 | 39.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 87 | 144 | $20,160 | $7,887 | 39.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 57 | 81 | $17,520 | $6,695 | 38.2% |
| 99211 | Established patient office or other outpatient visit, typically 5 minutes | Office | 2020 | 15 | 15 | $975.00 | $296.12 | 30.4% |
About Dr. Recaredo Berbano, MD
Dr. Recaredo Berbano, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942275748.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Recaredo Berbano, MD has received a total of $340,374 in payments from pharmaceutical and medical device companies, with $2,161 received in 2024. These payments were reported across 1,699 transactions from 54 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($247,441).
As a Medicare-enrolled provider, Berbano has provided services to 871 Medicare beneficiaries, totaling 1,315 services with total Medicare billing of $102,617. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location New York, NY
- Active Since 02/23/2006
- Last Updated 12/01/2023
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1942275748
Products in Payments
- JARDIANCE (Drug) $48,391
- FARXIGA (Drug) $38,093
- Ozempic (Drug) $30,321
- SOLIQUA (Drug) $28,385
- INVOKANA (Drug) $25,479
- TOUJEO (Drug) $23,322
- BYDUREON (Drug) $19,269
- RYBELSUS (Drug) $17,441
- CONTRAVE (Drug) $12,676
- Xultophy 100/3.6 (Drug) $11,232
- SOLIQUA 100/33 (Drug) $11,073
- Tresiba (Drug) $11,014
- Victoza (Drug) $9,667
- SOTAGLIFLOZIN (Drug) $5,138
- Androgel (Drug) $5,136
- SOLIQUA 100/33 (Biological) $4,167
- Korlym (Drug) $3,930
- Wegovy (Drug) $3,316
- Saxenda (Drug) $3,186
- TOUJEO (Biological) $1,856
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in New York
Dr. John Bilezikian, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $970,936
Endocrinology, Diabetes & Metabolism $970,936
Anastasios Manessis, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $719,303
Endocrinology, Diabetes & Metabolism $719,303
Stuart Weiss, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $520,227
Endocrinology, Diabetes & Metabolism $520,227
Dr. Brian Levy, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $383,360
Endocrinology, Diabetes & Metabolism $383,360
Dr. Jason Baker, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $308,409
Endocrinology, Diabetes & Metabolism $308,409
Dr. Henry Ginsberg, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $291,638
Endocrinology, Diabetes & Metabolism $291,638